Hypoparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.
The Hypoparathyroidism pipeline drugs market research report provides a comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects.
Hypoparathyroidism Pipeline Drugs Market Segmentation by Targets
The key targets in the Hypoparathyroidism pipeline drugs market are Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Extracellular Calcium Sensing Receptor, and Parathyroid Hormone 2 Receptor.
Hypoparathyroidism Pipeline Drugs Market Analysis, by Targets
For more insights on Hypoparathyroidism pipeline drugs targets, download a free report sample
Hypoparathyroidism Pipeline Drugs Market Segmentation by Key Mechanism of Actions
The key mechanism of actions in the Hypoparathyroidism pipeline drugs market are Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Extracellular Calcium Sensing Receptor Antagonist, and Parathyroid Hormone 2 Receptor Agonist.
Hypoparathyroidism Pipeline Drugs Market Analysis, by Mechanism of Actions
For more insights on Hypoparathyroidism pipeline drugs mechanism of actions, download a free report sample
Hypoparathyroidism Pipeline Drugs Market Segmentation by Key Routes of Administration
The key routes of administration in the Hypoparathyroidism pipeline drugs market are subcutaneous, oral, inhalational, and parenteral.
Hypoparathyroidism Pipeline Drugs Market Analysis, by Routes of Administration
For more insights on Hypoparathyroidism pipeline drugs routes of administration, download a free report sample
Hypoparathyroidism Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Hypoparathyroidism pipeline drugs market are recombinant peptide, protein, cell therapy, fusion protein, peptide, recombinant protein, small molecule, and synthetic peptide.
Hypoparathyroidism Pipeline Drugs Market Analysis, by Molecule Types
For more insights on Hypoparathyroidism pipeline drugs molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the Hypoparathyroidism pipeline drugs market are Ascendis Pharma AS, Aerami Therapeutics Inc, Aeterna Zentaris Inc, Amolyt Pharma, BridgeBio Pharma Inc, Eli Lilly and Co, Entera Bio Ltd, Extend Biosciences Inc, GC Biopharma Corp, MBX Biosciences Inc, ProLynx LLC, and Rani Therapeutics LLC.
Hypoparathyroidism Pipeline Drugs Market Analysis, by Companies
To know more about the leading players in the Hypoparathyroidism pipeline drugs market, download a free report sample
Hypoparathyroidism Pipeline Drugs Market Overview
Key Targets | Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Extracellular Calcium Sensing Receptor, and Parathyroid Hormone 2 Receptor |
Key Mechanism of Actions | Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Extracellular Calcium Sensing Receptor Antagonist, and Parathyroid Hormone 2 Receptor Agonist |
Key Routes of Administration | Subcutaneous, Oral, Inhalational, and Parenteral |
Key Molecule Types | Recombinant Peptide, Protein, Cell Therapy, Fusion Protein, Peptide, Recombinant Protein, Small Molecule, and Synthetic Peptide |
Leading Companies | Ascendis Pharma AS, Aerami Therapeutics Inc, Aeterna Zentaris Inc, Amolyt Pharma, BridgeBio Pharma Inc, Eli Lilly and Co, Entera Bio Ltd, Extend Biosciences Inc, GC Biopharma Corp, MBX Biosciences Inc, ProLynx LLC, and Rani Therapeutics LLC |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aeterna Zentaris Inc
Amolyt Pharma
Ascendis Pharma AS
BridgeBio Pharma Inc
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Biopharma Corp
MBX Biosciences Inc
ProLynx LLC
Rani Therapeutics LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Hypoparathyroidism pipeline drugs market?
The key targets in the Hypoparathyroidism pipeline drugs market are Parathyroid Hormone Receptor, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor, Extracellular Calcium Sensing Receptor, and Parathyroid Hormone 2 Receptor.
-
What are the key mechanism of actions in the Hypoparathyroidism pipeline drugs market?
The key mechanism of actions in the Hypoparathyroidism pipeline drugs market are Parathyroid Hormone Receptor Agonist, Parathyroid Hormone/Parathyroid Hormone Related Peptide Receptor Agonist, Extracellular Calcium Sensing Receptor Antagonist, and Parathyroid Hormone 2 Receptor Agonist.
-
What are the key routes of administration in the Hypoparathyroidism pipeline drugs market?
The key routes of administration in the Hypoparathyroidism pipeline drugs market are subcutaneous, oral, inhalational, and parenteral.
-
What are the key molecule types in the Hypoparathyroidism pipeline drugs market?
The key molecule types in the Hypoparathyroidism pipeline drugs market are recombinant peptide, protein, cell therapy, fusion protein, peptide, recombinant protein, small molecule, and synthetic peptide.
-
Which are the leading companies in the Hypoparathyroidism pipeline drugs market?
The leading companies in the Hypoparathyroidism pipeline drugs market are Ascendis Pharma AS, Aerami Therapeutics Inc, Aeterna Zentaris Inc, Amolyt Pharma, BridgeBio Pharma Inc, Eli Lilly and Co, Entera Bio Ltd, Extend Biosciences Inc, GC Biopharma Corp, MBX Biosciences Inc, ProLynx LLC, and Rani Therapeutics LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.